Melanoma is the second most common form of cancer for young adults 15-29 years old.
Combination antibody therapy shows promise in metastatic melanoma (Science Daily)
A duo of monoclonal antibodies -- ipilimumab and bevacizumab -- each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial.
- About Us
- Skin Cancer
- Member Section